A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.
Open Access
- 1 July 1992
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 55 (7), 630-631
- https://doi.org/10.1136/jnnp.55.7.630-a
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonistsNature, 1991
- NMDA antagonists potentiate antiparkinsonian actions of L‐dopa in monoamine‐depleted ratsAnnals of Neurology, 1990
- Excitatory amino acid antagonists and Parkinson's diseaseTrends in Neurosciences, 1990
- IFENPRODIL AND SL-82.0715 AS CEREBRAL ANTIISCHEMIC AGENTS .3. EVIDENCE FOR ANTAGONISTIC EFFECTS AT THE POLYAMINE MODULATORY SITE WITHIN THE N-METHYL-D-ASPARTATE RECEPTOR COMPLEX1990
- Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonismLife Sciences, 1990
- IFENPRODIL IS A NOVEL TYPE OF N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST - INTERACTION WITH POLYAMINES1989
- IFENPRODIL AND SL-82.0715 AS CEREBRAL ANTI-ISCHEMIC AGENTS .2. EVIDENCE FOR N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST PROPERTIES1988